COUGH is the #7 most commonly reported adverse reaction for NIRMATRELVIR AND RITONAVIR, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 2,041 FDA adverse event reports linking NIRMATRELVIR AND RITONAVIR to COUGH. This represents approximately 1.8% of all 110,406 adverse event reports for this drug.
NIRMATRELVIR AND RITONAVIR has an overall safety score of 75 out of 100. Patients taking NIRMATRELVIR AND RITONAVIR who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COUGH2,041 of 110,406 reports
COUGH is a less commonly reported adverse event for NIRMATRELVIR AND RITONAVIR, but still significant enough to appear in the safety profile.
Other Side Effects of NIRMATRELVIR AND RITONAVIR
In addition to cough, the following adverse reactions have been reported for NIRMATRELVIR AND RITONAVIR:
COUGH has been reported as an adverse event in 2,041 FDA reports for NIRMATRELVIR AND RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COUGH with NIRMATRELVIR AND RITONAVIR?
COUGH accounts for approximately 1.8% of all adverse event reports for NIRMATRELVIR AND RITONAVIR, making it a notable side effect.
What should I do if I experience COUGH while taking NIRMATRELVIR AND RITONAVIR?
If you experience cough while taking NIRMATRELVIR AND RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.